News | Deep Vein Thrombosis (DVT) | July 07, 2017

ACCESS PTS Study Demonstrates Efficacy of Ekos Therapy for Post-Thrombotic Syndrome

Participants saw an average reduction of symptoms from severe down to borderline mild

ACCESS PTS Study Demonstrates Efficacy of EKOS Therapy for Post-Thrombotic Syndrome

July 7, 2017 — BTG plc recently highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th Annual Scientific Sessions, June 14-17 in New Orleans. The study found chronic deep vein thrombosis (DVT) patients with post-thrombotic syndrome (PTS) can be treated safely and effectively with Ekos therapy. The ACCESS PTS protocol using Ekos therapy is now the only treatment regimen proven to significantly reduce the signs and symptoms of PTS and show a significant improvement in quality of life, according to the company.

The ACCESS PTS study is a multicenter prospective single-arm study of 73 patients with iliofemoral DVT, meeting eligibility including a Villalta Score of 8 or greater (Villalta Score measures the signs and symptoms of PTS), and who had failed three months of conservative therapy. Patients were treated with anticoagulation drugs followed by Ekos therapy with balloon dilatation.

The study met its primary efficacy endpoint and showed a significant improvement of Villalta Scores of 34 percent at 30 days across 77 limbs treated among the 73 patients with a p-value of <0.0001. On average, patients treated in the study experienced a symptom reduction from severe down to borderline mild. The study also showed a 21 percent improvement in patients’ quality of life. There was one bleeding incident and one pulmonary embolism (PE), meeting the study’s safety endpoint.

“ACCESS PTS demonstrates that Ekos therapy with balloon dilatation is effective and safe in reducing the signs and symptoms of post-thrombotic syndrome for patients suffering from chronic deep vein thrombosis, while improving their quality of life,” said lead investigator Mark Garcia, M.D., of Vascular & Interventional Associates of Delaware in Wilmington, Del. “EKOS therapy is a useful and important option for physicians treating debilitating chronic DVT and PTS.”

In addition to Garcia, the study’s authors include Keith Sterling, M.D., of Inova Alexandria Hospital, Alexandria, Va.; Michael Jaff, DO, of Newton-Wellesley Hospital, Boston; Kenneth Ouriel, M.D., of Syntactx; Susan Kahn, M.D., of Jewish General Hospital, Pelham, N.Y.; and Anthony Comerota, M.D., of Jobst Vascular Institute, Toledo, Ohio.

Watch the VIDEO: How the Ekos Thrombolytic Technology Works to Dissolve Clots."

Read the article “Ultrasound-assisted Catheter-directed Thrombolysis Reduces Treatment Risks for Pulmonary Emboli.”

For more information:

Related Content

Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init